Upneeq and nonsurgical ptosis treatment

Surgery remains the standard treatment for ptosis; oxymetazoline is described in the periorbital rejuvenation literature as a nonsurgical option that sits alongside surgery rather than replacing it (PMID 38348575).

Who qualifies

• The FDA label indication is acquired blepharoptosis in adults; safety and effectiveness have not been established in patients under 13 (FDA label, DailyMed). Congenital ptosis and ptosis from poor levator function are not what the drug was tested on; see Droopy eyelids for those causes.
• The label lists no contraindications, but warns that ptosis can be the presenting sign of stroke, cerebral aneurysm, Horner syndrome, myasthenia gravis, external ophthalmoplegia, or an orbital mass, and advises considering those conditions before treating ptosis with decreased levator function or other neurologic signs (FDA label, DailyMed).
• The label advises caution in patients with severe or unstable cardiovascular disease, orthostatic hypotension, uncontrolled hypertension or hypotension, cerebral or coronary insufficiency, Sjögren's syndrome, or untreated narrow-angle glaucoma, because alpha-adrenergic agonists as a class can affect blood pressure and pupil dynamics (FDA label, DailyMed).
• A poor response to the in-office phenylephrine test, which predicts the outcome of Müller muscle surgery, does not rule out a response to topical oxymetazoline; patients who respond poorly to phenylephrine can still benefit from the drops (PMID 39495666).
• Among 94 eye-clinic patients age 50 or older screened for ptosis, 73.4% had ptosis in at least one eye by self-assessment, 25.5% with asymmetric lids; among those eligible for treatment, 19.7% were willing to accept it (PMID 38223816).
• The drug is also used off-label for ptosis from other causes: a myasthenia gravis patient's ptosis resolved within 2 hours of one drop, with a 15-point gain on a 36-point visual field test, lasting at least 7 hours (PMID 34510144); 8 patients with severe botulinum toxin-induced ptosis (all over 3 mm) improved with pretarsal botulinum toxin injections alone or combined with oxymetazoline drops (PMID 36943792). Botulinum-induced ptosis has a mean onset of 3 to 14 days after injection and otherwise resolves on its own as the toxin wears off (PMID 34378298).

How it works

• Oxymetazoline is an alpha-adrenoceptor agonist that acts on Müller's muscle, the smaller, sympathetically driven lid-elevating muscle beneath the levator (FDA label, DailyMed).
• Dosing is one drop in one or both ptotic eyes once daily, from a single-use, preservative-free container; contact lenses are removed before instillation and can go back in 15 minutes later (FDA label, DailyMed).
• After ocular dosing, oxymetazoline reaches a median peak blood concentration at 2 hours (range 0.5-12 hours), with a mean peak concentration of 30.5 pg/mL and a terminal half-life of 8.3 hours (range 5.6-13.9 hours) (FDA label, DailyMed).
• Onset at the eyelid is faster than the blood level suggests: in a pooled analysis of 203 patients on oxymetazoline and 101 on vehicle, MRD1 increased by a mean 0.59 mm at 5 minutes and 0.93 mm at 15 minutes on day 1 (both p<0.001 against vehicle), with similar gains on days 14 and 42 (PMID 34211263).

Results and evidence

• The two pivotal phase 3 trials (FDA label: Trial 1, RVL-1201-201) enrolled 140 subjects (94 oxymetazoline, 46 vehicle, mean age 64) and Trial 2 (RVL-1201-202) enrolled 164 subjects (109 oxymetazoline, 55 vehicle, mean age 63), each dosed once daily for 42 days; the primary endpoint, the Leicester Peripheral Field Test, improved significantly against vehicle at 2 and 6 hours in both trials (FDA label, DailyMed).
• A pooled analysis of those same two trials, 304 patients, found oxymetazoline increased points seen on the Leicester field test by 7.1 against 2.4 with placebo at day 14 (PMID 33001144).
• A meta-analysis of 4 randomized trials, 448 patients, found oxymetazoline raised the lid a mean 0.65 mm against 0.26 mm with placebo (PMID 40881581). A separate systematic review of 5 studies, 458 patients, found a posttreatment MRD1 gain of 1.40 mm and a gain of 0.83 mm over controls, with high heterogeneity between studies (I² 85-95%) (PMID 39172003).
• In a randomized trial of patients without severe ptosis, 114 patients, MRD1 rose 0.9 mm against -0.3 mm with placebo at 2 hours (p<0.001), and eye redness fell more with oxymetazoline (p=0.002) (PMID 36996503).
• In 29 aesthetic patients, mean MRD1 rose from 2.3 mm to 4.2 mm 2 hours after a single drop (p<0.01), and the sclera became measurably whiter in 57 of 58 eyes; brow position did not change (PMID 34962512).
• A Japanese phase 3 trial (a separate regulatory filing from the FDA product), 336 patients randomized to once-daily, twice-daily, or placebo, found MRD1 at day 14 improved 0.59 mm over placebo with once-daily dosing (95% CI 0.38-0.79 mm, p<0.05), and found no loss of effect through 6 months of use (PMID 41961227).

Risks and complications

• The FDA label's most common adverse reactions (1-5% of patients) are punctate keratitis, conjunctival hyperemia, dry eye, blurred vision, instillation site pain, eye irritation, and headache, from 360 subjects treated for at least 6 weeks across three Phase 3 trials (FDA label, DailyMed).
• Pooled safety data from 4 randomized trials, 568 patients (median age 66, 74.8% female), found treatment-emergent adverse events in 31.2% on oxymetazoline against 30.6% on vehicle, nearly all mild to moderate; no individual ocular adverse event exceeded 3.5% of patients, and more than 98% rated the drop as causing no or mild discomfort (PMID 34675472).
• A 2026 analysis of the FDA Adverse Event Reporting System, covering January 7, 2020 (FDA approval) through April 30, 2025, found 306 patients with 658 adverse events; it confirmed the label's listed effects and identified signals not on the label: vitreoretinal complications in 3.2% (retinal detachment, vitreous detachment, vitreous floaters, and vitreous hemorrhage, each 0.8%), mydriasis in 5.6% (reporting odds ratio 175.4), hypertension in 1.6% (reporting odds ratio 3.2), and tachyphylaxis (waning response with repeated use) in 1.3% (reporting odds ratio 5.1) (PMID 41949436).
• The label warns of a risk of angle-closure glaucoma in patients with untreated narrow-angle glaucoma and advises against touching the dropper tip to the eye or any surface, to avoid injury or contamination (FDA label, DailyMed).

Duration of effect

• In the pooled phase 3 data, the eyelid-elevating effect was still statistically significant against vehicle 2 to 6 hours after dosing on both day 1 and day 14, and the same rapid onset was observed again on day 42, showing no loss of effect over 6 weeks of daily use (PMID 34211263).
• The Japanese phase 3 trial found no loss of effect through 6 months of once- or twice-daily dosing (PMID 41961227).
• In one individual myasthenia gravis case, a single drop kept the ptosis resolved for at least 7 hours (PMID 34510144); the drug's own blood half-life is 8.3 hours (FDA label, DailyMed), consistent with once-daily dosing. The AFAERS analysis above found tachyphylaxis reported in 1.3% of adverse events with continued use (PMID 41949436).

Other nonsurgical options

• Apraclonidine 0.5% (brand name Iopidine), also an alpha-adrenergic agonist on Müller's muscle, raises the lid 1 to 3 mm and has been used off-label for ptosis after botulinum toxin injection, though published data on this use remain limited (PMID 15748550). In a pilot trial of 10 myasthenia gravis patients, apraclonidine raised mean palpebral fissure height from 8.8 mm to 14.2 mm and MRD1 from 1.7 mm to 5.4 mm within 60 minutes, with improvement starting as early as 1 minute (PMID 37259693). A 2025 American Academy of Ophthalmology review of 26 studies on ptosis drops found apraclonidine, naphazoline, and oxymetazoline all produce short-term lid elevation, but named oxymetazoline 0.1% as the only agent with FDA approval for treatment rather than diagnosis (PMID 40172501).
• A ptosis crutch (a bar attached to eyeglasses that mechanically props the lid) and eyelid taping remain in clinical use; in a survey of 9 vision-rehabilitation optometrists, the ptosis crutch, eyelid taping, and oxymetazoline drops were the most commonly reported current management options, each named by 6 of 9 respondents (PMID 37889985).
• A magnetic levator prosthesis, a spectacle-mounted device that holds the lid open with magnetic force, is in early clinical testing; of 9 surveyed optometrists, most said cost and insurance coverage were the main barriers to offering it (PMID 37889985).
• A 2026 review for dermatologic surgeons states that off-label adrenergic agents and targeted pretarsal botulinum toxin injections may offer adjunctive benefit for mild acquired ptosis, though the supporting evidence for both remains limited (PMID 42319274).

Current questions

• The AAO's 2025 review concluded that independent validation of oxymetazoline's long-term efficacy and safety remains needed, beyond the sponsor-run trials that supported approval (PMID 40172501).
• The FDA Adverse Event Reporting System signals for vitreoretinal complications, hypertension, and tachyphylaxis were not on the original label and need confirmation in controlled studies (PMID 41949436).
• Why a poor phenylephrine test response does not predict a poor oxymetazoline response is not established (PMID 39495666).
• Adoption of mechanical and device-based alternatives (ptosis crutch, magnetic levator prosthesis) is limited mainly by cost and insurance coverage rather than by clinical performance, according to the clinicians surveyed (PMID 37889985).

Terms

• Oxymetazoline hydrochloride 0.1%: an alpha-adrenergic agonist ophthalmic solution, brand name Upneeq, FDA-approved for acquired blepharoptosis in adults (FDA label, DailyMed).
• Müller's muscle: a smaller, sympathetically driven lid-elevating muscle beneath the levator, the drug's site of action (FDA label, DailyMed).
• MRD1: the distance from the corneal light reflex to the upper lid margin, the standard trial measurement of lid height (PMID 34211263).
• Leicester Peripheral Field Test (LPFT): a visual field test used as the primary efficacy endpoint in the pivotal trials (FDA label, DailyMed).
• Phenylephrine test: an in-office eyedrop test that predicts the result of Müller muscle surgery; a poor response to it does not rule out benefit from oxymetazoline (PMID 39495666).
• Apraclonidine (Iopidine): an alpha-adrenergic eyedrop also used off-label to raise a drooping lid, including after botulinum toxin injection (PMID 15748550).
• Ptosis crutch: a bar attached to eyeglasses that mechanically holds the eyelid open (PMID 37889985).
• Magnetic levator prosthesis: a spectacle-mounted device that holds the lid open with magnetic force (PMID 37889985).
• Tachyphylaxis: a waning drug response with repeated use, reported as a safety signal for oxymetazoline in real-world adverse event data (PMID 41949436).
• Reporting odds ratio (ROR): a measure of how much more often an adverse event is reported for a drug than for all other drugs in a safety database, used in the FDA Adverse Event Reporting System analysis (PMID 41949436).

Papers